Skip to main content
. 2017 Oct 12;39(1):74–84. doi: 10.1038/aps.2017.129

Figure 3.

Figure 3

Osthole inhibited the metabolic activation of APAP and promoted APAP clearance. Mice were intraperitoneally treated with osthole (100 mg/kg) for 3 consecutive days. On the fourth day, APAP (300 mg/kg) and osthole were simultaneously administered to mice. Mice were sacrificed at 6 h post-APAP. (A, B) The mRNA levels of phase I enzymes in the liver were quantified using real-time PCR. (C) Hepatic CYP2E1 levels were determined using ELISA. (D-G) The mRNA levels of phase II enzymes in the liver were quantified using real-time PCR. (H) Hepatic SULT2A1 and UGT1A1 levels were determined by Western blotting. Data are expressed as the mean±SEM. n=4–6 mice per group. *P<0.05, **P<0.01 compared to control. #P<0.05, ##P<0.01 compared to APAP.